UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14A-101)
SCHEDULE 14A INFORMATION
INFORMATION STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. ___)
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary Information Statement
[ ] Confidential, for use of the Commission only (as permitted by Rule
14a-6(e)(2)).
[ ] Definitive proxy statement.
[X] Definitive additional materials.
[ ] Soliciting material under Rule 14a-12.
ENDOVASC, INC.
(Name of Registrant as Specified in its Charter)
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth amount on which
filing fee is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offering fee was
paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of the filing.
1) Amount previously paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
Endovasc Announces Annual Shareholders' Meeting
MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 27, 2004--Endovasc, Inc. (OTCBB:EVSC -
----
News), a Business Development Company focused on innovative drug development,
- ----
announces its Annual Meeting of Stockholders to be held at Havens Landing, 19785
State Highway 105 West, Montgomery, Texas, on November 19, 2004 at 2 PM, CST.
Dr. Diane Dottavio, Chief Executive Officer, remarks, "This year's annual
shareholder meeting will discuss Endovasc's initiatives to refocus our clinical
strategy and prioritize product goals as part of a new business plan to meet the
company's objectives in 2005."
The agenda for the meeting addresses three main issues posed by the Board. The
first is the election of one director to serve for a three-year term and until
his or her successor is elected and qualified. Secondly, the Board seeks to
ratify the selection of Ham, Langston & Brezina LLP as independent auditors for
the fiscal year ending June 30, 2005 and thirdly, Endovasc wishes to amend the
Company's Articles of Incorporation to increase the number of shares of Common
Stock.
The record date for the Annual Meeting is October 19, 2004. Holders of Common
Stock and holders of the Company's Series NDC Common Stock of record as of
October 19, 2004 are entitled to notice of and to vote at the Annual Meeting.
About Endovasc, Inc.
Endovasc, Inc., established in 1996, is a Business Development Company focused
on innovative drug development in the areas of cardiovascular and metabolic
medicine. Endovasc's Subsidiaries include; Liprostin Incorporated, which holds
the intellectual property for a liposomal based treatment to increase
circulation, and reduce leg pain in patients suffering from vascular disease;
Angiogenix Limited which poses the sublicense for an isomer of nicotine that has
shown to recruit the body's own stem cells that help grow new blood vessels,
aiming to relieve chest pain and improve heart function in patients with chronic
myocardial ischemia; and Nutraceutical Development Corporation (OTC:EVSD - News)
---- ----
which has an agreement in place with an innovative product development company
to commercialize its muscle mass enhancing product.
For more information about Endovasc, please visit www.endovasc.com.
----------------
Safe Harbor Statement
All statements other than statements of historical fact included in this press
release are "forward-looking statements." The forward-looking statements,
including statements about the Company's future expectations, including future
revenues and earnings, and all other forward-looking statements (i.e., future
operational results and sales) are subject to assumptions and beliefs based on
current information known to the Company and factors that are subject to
uncertainties, risk and other influences, which are outside the Company's
control, and may yield results differing materially from those anticipated.
- ------------------------
Contact:
Investor Relations for Endovasc Inc.
David Zazoff, 212-505-5976
PressReleases@za-consulting.net
-------------------------------